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Abstract
Introduction: This study evaluates an insulin dose titration model and factors that impact insulin dose adjustment in Chinese adults with 
type-2 diabetes, who receive basal insulin in real-world settings.
Material and methods: A total of 19,894 patients from the ORBIT study were included. These patients were divided into four groups, 
according to the type of insulin dose adjustment: no insulin titration (group A), self-titration (group B), physician-led insulin titration 
(group C), and combined physician and patient-led insulin titration (group D). Data were collected and compared at baseline and after 
six months of treatment.
Results: A total of 12,865 patients completed the visits and were included in the analysis. Among these patients, 3187 (24.8%), 1971 (15.3%), 
5165 (40.1%), and 2542 (19.8%) patients were included in groups A, B, C, and D, respectively. The multivariate logistic regression analysis 
revealed that the duration of diabetes, body mass index, microvascular complications, inpatient days, HbA1C level, and self-monitoring 
of blood glucose (SMBG) were positively correlated with insulin titration in group B, C, and D, compared with group A. The number of 
inpatient days and outpatient visits were positively correlated with dose adjustment for physician-led titration, while this was negatively 
correlated for self-titration. Self-titration encouraged by physicians and home blood glucose monitoring were positively correlated with 
self-titration and the combined physician and patient-led titration.
Conclusions: High HbA1C level, SMBG, long disease duration, microvascular complications, and the encouragement of physicians while 
initiating insulin use prompt patients to perform dose adjustments in real-world settings. (Endokrynol Pol 2018; 69 (4): 395–402)
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Streszczenie
Wstęp: Badanie ma na celu ocenę modelu dostosowywania dawki insuliny i czynników, mających wpływ na dostosowanie dawki insuliny 
u chińskich dorosłych pacjentów z cukrzycą typu 2 leczonych podstawową dawką insuliny w warunkach rzeczywistych.
Materiał i metody: W badaniu udział wzięło 19 894 pacjentów z badania ORBIT, którzy zostali podzieleni na 4 grupy, w zależności od 
typu dostosowywania dawki insuliny: brak dostosowywania dawki insuliny (grupa A), samodzielne dostosowywanie dawki (grupa B), 
dostosowywanie dawki przez lekarza (grupa C) oraz dostosowywanie dawki zarówno przez lekarza jak i przez pacjenta (grupa D). Dane 
zostały zebrane i porównane na początku badania i po 6 miesiącach leczenia. 
Wyniki: Łącznie 12 865 pacjentów ukończyło wizyty i zostało uwzględnionych w analizie. Spośród tych pacjentów, 3187 (24,8%), 1971 
(15,3%), 5165 (40,1%) i 2542 (19,8%) badanych włączono odpowiednio do grup A, B, C i D. Wieloczynnikowa analiza regresji logistycznej 
wykazała, że czas trwania cukrzycy, wskaźnik masy ciała, powikłania mikronaczyniowe, dni hospitalizacji, stężenie HbA1C i samokontrola 
stężenia glukozy we krwi (self-monitoring of blood glucose; SMBG) były dodatnio skorelowane z dostosowywaniem insuliny w grupach 
B, C i D w porównaniu z grupą A. Liczba dni hospitalizacji i wizyt ambulatoryjnych były dodatnio skorelowane z dostosowywaniem 
dawek przez lekarza i ujemnie skorelowane z samodzielnym dostosowywaniem dawki. Zachęcanie przez lekarzy do samodzielnego do-
stosowywania dawki i monitorowanie stężenia glukozy we krwi w warunkach domowych były dodatnio skorelowane z samodzielnym 
dostosowywaniem dawki oraz dostosowywaniem dawki zarówno przez lekarza, jak i przez pacjenta.
Wnioski: Wysokie stężenie HbA1C, samokontrola stężenia glukozy we krwi, długi czas trwania choroby, powikłania mikronaczyniowe 
oraz zachęta lekarzy podczas inicjowania podawania insuliny skłaniają pacjentów do dostosowywania dawek w warunkach rzeczywistych. 
(Endokrynol Pol 2018; 69 (4): 395–402) 
Słowa kluczowe: cukrzyca typu 2, podstawowa insulinoterapia, edukacja diabetologiczna, warunki rzeczywiste, badanie ORBIT
Yingli Chen, Department of Endocrinology, Peking University People’s Hospital, NO.11 Xizhimen South Street, Xicheng District, Beijing 
100044, China. E-mail: yinglichen_dr@163.com
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Introduction
T2DM is one of the most common diseases that en-
dangers public health. A survey conducted by the 
World Health Organisation in 2011 revealed that the 
prevalence of diabetes worldwide was 346 million, and 
according to the International Diabetes Federation, 
this number is estimated to reach 552 million by 2030, 
globally. Furthermore, China has been reported to have 
the highest incidence of diabetes worldwide. In China, 
the morbidity rate among adult patients with T2DM is 
approximately 9.8%, in which 92.4 million adults suffer 
from the disease [1]. T2DM may lead to diabetes-related 
microvascular complications, which in turn play a major 
role in exacerbating macrovascular complications. The 
increasing prevalence of diabetes is expected to pose 
a heavy economic burden on society, and the adequate 
glycaemic control of diabetes patients has been shown 
to be effective in reducing the incidence of diabetes-
related complications, especially in the early stages of the 
disease [2–4]. Thus, several countries, including China, 
have published diabetes control guidelines that recom-
mend the control of glycated haemoglobin (HbA1C) lev-
els below 7% [5, 6]. Although significant advancements 
have been made in diabetes drug research in recent 
years, achieving and maintaining the goal of HbA1C 
< 7% remains challenging for healthcare providers and 
patients worldwide. A survey [7] conducted in the US 
revealed that the rate of achieving good glycaemic con-
trol in diabetes patients was 52.9%, while recent studies 
have shown that this rate was only 39.7% in China [8].
The natural progression of the disease leads to the 
gradual regression of islet cell function, resulting in 
an increase in blood glucose. Therefore, to control the 
blood glucose below a standard level, exogenous insu-
lin treatment is needed when oral medications fail to 
control the HbA1C level within the compliance range. 
Guidelines from different countries recommend the use 
of basal insulin in combination with oral antidiabetes 
drugs (OADs) to improve glycaemic control [6]. How-
ever, in clinical practice, introducing insulin treatment 
remains challenging. Studies [9, 10] have shown that, 
overall, 26.9–58.0% of patients across various countries 
are reluctant to accept insulin treatment, which inter-
feres with the timely initiation of insulin treatment 
after the onset of hyperglycaemia. On the other hand, 
another important factor that affects glycaemic control 
is insulin dose adjustments following insulin treatment 
initiation. Numerous randomised, controlled clinical 
studies have confirmed the efficacy and safety of insu-
lin treatment. However, these studies were conducted 
under the guidance and close observation of a physi-
cian. A study [11] conducted in China revealed that in 
clinical practice, only 27% of T2DM patients controlled 
their HbA1C below the normal range following insulin 
treatment initiation. However, at present, no study has 
assessed actual insulin dose adjustments and the factors 
that influence dose adjustment in Chinese patients with 
T2DM. The present study used data from the Obser-
vational Registry of Basal Insulin Treatment (ORBIT) 
study [12], which includes a large sample size, in order 
to understand the present clinical practice of insulin 
dose adjustment following the initiation of insulin treat-
ment. In addition, a dose titration model was applied 
to compare the differences in insulin dose adjustment 
across various groups at baseline and after six months 
of treatment. Also, factors that may affect insulin dose 
adjustment in this model were investigated.
Material and methods
Study objectives
The primary objective of this analysis was to under-
stand the pattern of insulin dose adjustment following 
basal insulin initiation in clinical practice in T2DM pa-
tients using a dose titration model, and to explore the 
factors that influence insulin dose adjustment following 
basal insulin initiation in the real world.
Overall design and subjects
Data were collected from patients in the ORBIT study. 
All participants provided written, informed consent. 
A total of 19,894 T2DM patients with uncontrolled 
HbA1C on OADs started using long-acting formula-
tions. These patients were divided into four groups, 
according to the type of insulin dose adjustment: no in-
sulin titration (group A), self-led insulin titration (group 
B), physician-led insulin titration (group C), and com-
bined physician and patient-led insulin titration (group 
D). Patients who stopped using insulin after the baseline 
visit and those who did not complete the follow-ups 
were excluded from the analysis. Data were recorded 
at baseline and at the follow-up visits after initiation of 
insulin treatment for a period of six months. Differences 
between the four groups were compared across the 
follow-up visits. Differences between the clinical data 
among different groups were also compared at baseline 
and after six months of treatment. In addition, each 
group was compared against the no-dose-adjustment 
group to explore the factors that influence insulin dose 
adjustment in patients.
Treatments
This was an observational study. None of the selected 
patients received basal insulin prior to enrolment. The 
selection of basal insulin formulations and dose adjust-
ments were based on the physician’s discretion and the 
patient’s needs.
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Data collection and assessments
Data on baseline demographics, education level, dia-
betes duration, treatment settings (inpatient or outpa-
tient), macrovascular complications, microvascular 
complications, and HbA1C level were collected. In ad-
dition, information on whether the patients performed 
the self-monitoring of blood glucose (SMBG) at baseline 
and after insulin treatment for six months, the fre-
quency of SMBG, whether the physicians encouraged 
patients to adjust their insulin dose, outpatient visits 
and inpatient days, hypoglycaemia events, HbA1C 
level, and out-of-pocket costs were recorded, in order 
to analyse and compare the characteristics of the four 
dose-adjustment groups. Furthermore, the same infor-
mation was also recorded during the follow-up visits 
to determine factors that influence patients to adjust 
their insulin dose. 
Statistics
The study population included patients treated with 
basal insulin for six months. The characteristics were de-
scribed for all participants, as well as for the individual 
groups. Continuous variables with normal distribution 
were summarised using descriptive statistics, and were 
presented as mean ± standard deviation (SD) values. 
Continuous variables of skewed distribution were 
reported as median and quartile. Discrete variables 
were presented as n (%). The statistical significance of 
differences between subpopulations was not reported 
because the sample was sufficiently large to establish 
significance. Multinomial logistic analyses were used 
to assess the independent associations in the insulin 
titration model.
Results
From December 2011 to June 2013, 19,894 patients with 
T2DM uncontrolled on OADs began receiving basal 
insulin [13]. Among these patients, 12,865 patients 
completed the visits and were included into the analy-
sis. The average age of these patients was 55.7 ± 10.6 
years, and 6829 (53.1%) of these patients were male. The 
average diabetes duration was 6.8 ± 5.3 years. Overall, 
3187 (24.8%) patients had no insulin titration (group A), 
1971 (15.3%) patients performed self-titration (group B), 
5165 (40.1%) patients underwent physician-led insulin 
titration (group C), and 2542 (19.8%) patients under-
went combined physician and patient-led insulin titra-
tion (group D). After six months of insulin treatment, 
41.7% of patients achieved the target of HbA1C < 7%. 
Glycated haemoglobin decreased by 2.2%. Among 
these patients, 48.3%, 36.6%, 40.9%, and 38.8% were 
from group A, B, C, and D, and glycated haemoglobin 
decreased by 2.3%, 2.1%, 2.1%, 2.3%, respectively. 
Furthermore, fasting blood glucose was 7.4 ± 2.2, 8.0 ± 2.5, 
7.7 ± 2.4, and 7.8 ± 2.4 mmol/L, while the frequency of 
hypoglycaemia was 0.2 ± 5.4, 3.2 ± 27.0, 1.8 ± 7.8, and 
4.3 ± 12.4 events in groups A, B, C, and D, respectively. 
No significant difference was noted between groups 
with regard to severe hypoglycaemia events. Overall, 
42.3%, 47.5%, 43.3%, and 49.3% of patients in group A, 
B, C, and D, respectively, performed home monitoring 
of blood glucose, and 23.0%, 14.0%, 41.4%, and 21.5% 
of patients in group A, B, C, and D, respectively, per-
formed SMBG. The frequency of SMBG in group A, B, 
C, and D was 5.3 ± 10.4, 5.8 ± 11.7, 5.0 ± 9.5, and 5.3 ± 
8.5 times during the six-month follow-up period, while 
the number of hospitalisation days was 0.5 ± 2.9, 0.6 ± 
5.1, 0.9 ± 4.6, and 0.9 ± 4.1, respectively, and the number 
of clinic visits was 4.6 ± 4.2, 4.1 ± 4.2, 6.9 ± 5.5, and 
6.2 ± 5.8, respectively. Table I summarises the baseline 
characteristics and demographics of patients in each 
group. Table II shows the efficacy and safety variables 
in the different titration groups.
Multinomial logistic regression analysis revealed 
that the duration of diabetes, body mass index (BMI), 
microvascular complications, inpatient treatment, 
HbA1C level, and SMBG at baseline were positively 
correlated with insulin titration (Table III).
The number of inpatient days and outpatient visits 
were positively correlated with dose adjustment in 
group C but were negatively correlated with dose 
adjustment in group B. Prior insulin therapy was posi-
tively correlated with self-dose titration and combined 
physician and patient-led dose titration. Compared 
with group A, the educational degree of patients was 
negatively correlated with dose adjustment in group C 
and D, but was positively correlated with dose adjust-
ment in group B. Initial insulin treatment at tertiary hos-
pitals was positively correlated with dose adjustment 
in group C and D. Encouragement of self-titration by 
physicians and home blood glucose monitoring were 
positively correlated with self-titration and combined 
physician and patient-led titration. The multivariate 
logistic regression analysis revealed that the level of 
hospitals where patients started to use insulin, gen-
der, OAD duration, and out-of-pocket costs were not 
correlated with insulin dose titration, compared with 
patients without insulin titration. 
Discussion
In the present observational study conducted in a real-
world clinical setting, after six months of basal insulin 
treatment, 3187 (24.8%) patients had no insulin titration 
(group A), 1971 (15.3%) patients performed self-titration 
(group B), 5165 (40.1%) patients underwent physician-
led insulin titration (group C), and 2542 (19.8%) patients 
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underwent combined physician and patient-led insulin 
titration (group D).
In group A 3187 (24.8%) patients did not adjust 
their insulin dose; the average age of these patients 
was higher compared to patients in groups B, C, and 
D. Patient age in the present study was negatively 
correlated with insulin dose adjustment. A possible 
reason is that elderly patients were afraid of the inci-
dence of hypoglycaemia, which highlights the need to 
educate elderly patients on how to adjust insulin usage 
in order to acquire good glycaemic control and avoid 
hypoglycaemia. Furthermore, patients who received 
their first basal insulin treatment in an inpatient setting 
accounted for the highest proportion of patients in this 
group compared with groups B, C, and D. HbA1C and 
fasting plasma glucose levels were lower in this group. 
Elevated blood glucose level may be a key factor for 
insulin dose adjustment. The present study revealed 
that HbA1C level was positively correlated with insulin 
dose titration. A meta-analysis [14] also revealed that 
a positive relationship between baseline HbA1C and 
the magnitude of HbA1C change (which is an indicator 
of glucose control level) is a key factor for insulin dose 
adjustment. In addition, fewer patients were encouraged 
Table I. Characteristics in different titration groups
Tabela I. Charakterystyka różnych grup dostosowywania dawki
Variables Overall A B C D
N 12,865 3187 1971 5165 2542
Hospital level
— secondary hospital 6855 (53.3%) 1663 (52.2%) 1028 (52.2%) 2779 (53.8%) 1385 (54.5%)
— tertiary hospital 6010 (46.7%) 1524 (47.8%) 943 (47.8%) 2386 (46.2%) 1157 (45.5%)
Gender (male) (%) 6829 (53.1%) 1738 (54.5%) 1089 (55.3%) 2651 (51.3%) 1351 (53.1%)
Age (years) 55.7 ± 10.2 56.1 ± 10.6 55.6 ± 10.1 55.9 ± 10.2 54.9 ± 9.8
— ≥ 60 4770 (37.1%) 1260 (39.5%) 724 (36.7%) 1936 (37.5%) 850 (33.4%)
BMI [kg/m2] 24.7 ± 3.3 24.6 ± 3.4 24.8 ± 3.4 24.6 ± 3.3 24.8 ± 3.3
Out of pocket 40.6 ± 26.6 38.1 ± 24.7 38.0 ± 26.9 42.3 ± 27.5 42.0 ± 26.4
Education degree
— primary school or illiterate 3288 (25.6%) 809 (25.4%) 432 (21.9%) 1376 (26.6%) 671 (26.4%)
— junior high school 3949 (30.7%) 940 (29.5%) 558 (28.3%) 1669 (32.3%) 782 (30.8%)
— senior high school 3326 (25.9%) 811 (25.4%) 583 (29.6%) 1285 (24.9%) 647 (25.5%)
— junior college or higher 2302 (17.9%) 627 (19.7%) 398 (20.2%) 835 (16.2%) 442 (17.4%)
Diabetes duration 6.8 ± 5.3 6.5 ± 5.4 7.1 ± 5.6 6.8 ± 5.2 6.9 ± 5.2
OAD Duration 6.0 ± 5.1 5.7 ± 5.1 6.3 ± 5.4 6.0 ± 5.0 6.1 ± 5.1
Patient resource
— out-patient clinic 5864 (45.6%) 968 (30.4%) 725 (36.8%) 2748 (53.2%) 1423 (56.0%)
— in-patient ward 7001 (54.4%) 2219 (69.6%) 1246 (63.2%) 2417 (46.8%) 1119 (44.0%)
Macro complication 2076 (16.1%) 492 (15.4%) 328 (16.6%) 798 (15.5%) 458 (18.0%)
Micro complication 3814 (29.6%) 925 (29.0%) 674 (34.2%) 1404 (27.2%) 811 (31.9%)
HbA1c 9.5 ± 2.0 9.4 ± 2.0 9.5 ± 1.9 9.6 ± 2.0 9.7 ± 2.0
Encouraged self-titration 4801 (37.3%) 975 (30.6%) 857 (43.5%) 1629 (31.5%) 1340 (52.7%)
Home blood glucose monitor at v1 5773 (44.9%) 1347 (42.3%) 937 (47.5%) 2235 (43.3%) 1254 (49.3%)
Home blood glucose monitor at v3 8398 (65.3%) 1889 (59.3%) 1416 (71.8%) 3191 (61.8%) 1902 (74.8%)
Have SMBG at v1 8692 (67.6%) 2001 (23.0%) 1221 (14.0%) 3600 (41.4%) 1870 (21.5%)
SMBG times at v1 # (times/month) 5.3 ± 9.9 5.3 ± 10.4 5.8 ± 11.7 5.0 ± 9.5 5.3 ± 8.5
Have SMBG at v3 10879 (84.6%) 2454 (77.0%) 1569 (79.6%) 4520 (87.5%) 2336 (91.9%)
SMBG times at v3 # (times/month) 6.5 ± 7.9 5.5 ± 7.4 6.6 ± 8.2 6.5 ± 7.8 7.5 ± 8.4
BMI, body mass index; HbA1C, glycated haemoglobin; OAD, oral antidiabetes drug; SMBG, self-monitoring of blood glucose; #use the nonparametric test — Kruskal- 
-Wallis H test
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to perform self-titration in this group; it is also one of 
the reasons of patients did not adjust insulin dose. The 
present study also revealed that the encouragement 
of doctors was positively correlated with insulin dose 
adjustment. A survey [15] conducted in China revealed 
that poor glucose control was partly correlated with 
a lack of diabetes education. 
The present study revealed that inpatient days and 
clinic visits were negatively correlated with self-titra-
tion. In group B, out-of-pocket costs were low, diabetes 
duration and OAD use were relatively longer, the rate 
of microvascular and macrovascular complications was 
low, and HbA1C control rate and hyperglycaemia and 
severe hyperglycaemia rates were similar to those in 
the other three groups. However, clinic visits and inpa-
tient days were lower compared with the other three 
groups. This finding is inconsistent with the results 
of the present study, in which patients started using 
insulin under inpatient treatment settings because in-
patient treatment costs can be reimbursed through the 
Chinese medical insurance system. Therefore, patients 
prefer starting insulin treatment in the ward instead 
of self-adjusting their insulin dose. Moreover, patients 
are sceptical regarding the safety of insulin adjustment 
when visiting clinics or when self-adjusting their insulin 
dose. Various randomised controlled studies [16–18] 
have shown that self-titration of insulin had similar 
efficacy to physician-led insulin titration. This suggests 
that it is necessary to instruct patients to conduct self-
led insulin titration, which would further strengthen 
the patient’s ability to manage their diabetes. In group 
B, more patients performed SMBG, compared to the 
other three groups. SMBG performance and higher 
frequency of SMBG had a positive effect on insulin 
dose adjustment in the present study.
Furthermore, in group C 5165 (40.1%) patients 
adopted physician-led insulin titration. The proportion 
of out-of-pocket costs and microvascular complications 
were higher in this group compared to the other three 
groups. Moreover, inpatient days and clinic visits were 
higher and SMBG frequency was lower in this group 
compared to the other three groups. The present study 
revealed that inpatient days and clinic visits were posi-
tively correlated with physician-led insulin dose adjust-
ment, and microvascular complications were positively 
correlated with insulin dose titration in the present study, 
which suggests that patients with long-term diabetes and 
diabetes-related microvascular complications focus more 
on glucose management for physicians and patients.
Lastly, 2542 (19.8%) of patients adopted combined 
physician and patient-led insulin titration (group D). 
Patients who received their first basal insulin treatment 
in an outpatient setting accounted for the highest pro-
portion of patients in this group. Patients in this group
had the highest HbA1C level, glucose control level 
is a key factor for physician and patient to make insulin 
titration.
It is noteworthy that in the present study, HbA1C 
levels were reduced from 9.5% ± 2.0% to 7.4% ± 1.3%, 
with a mean reduction of 2.2% ± 2.0%. Overall, 41.7% 
of patients had HbA1C < 7%, of which 48.3%, 36.6%, 
40.9%, and 38.8% of these patients were from group A, 
Table II. Effect and safety variable description in different titration groups
Tabela II. Opis zmiennej efektu i zmiennej bezpieczeństwa w różnych grupach dostosowywania dawki
Variables Overall 
12,816
A 
3171
B 
1951
C 
5157
D 
2537
HbA1c control (< 7%) 5342 (41.7%) 1533 (48.3%) 715 (36.6%) 2109 (40.9%) 985 (38.8%)
HbA1c at v3 7.4 ± 1.3 7.1 ± 1.2 7.5 ± 1.5 7.4 ± 1.3 7.5 ± 1.4
HbA1c v3-v1 –2.2 –2.3 –2.1 –2.1 –2.1
FPG control (< 7 mmol/L) 3867 (45.3%) 995 (51.5%) 433 (40.7%) 1685 (45.0%) 754 (41.9%)
FPG (mmol/L) 7.7 ± 2.4 7.4 ± 2.2 8.0 ± 2.5 7.7 ± 2.4 7.8 ± 2.4
Severe hypoglycaemia 69 (0.5%) 11 (0.3%) 15 (0.8%) 18 (0.3%) 25 (1.0%)
Severe hypoglycaemia times 0.0 ± 0.6 0.0 ± 0.7 0.1 ± 0.7 0.0 ± 0.4 0.1 ± 0.6
Ordinary hypoglycaemia 1186 (9.2%) 133 (4.2%) 204 (10.4%) 402 (7.8%) 447 (17.6%)
Ordinary hypoglycaemia times 2.3 ± 13.3 0.9 ± 5.4 3.2 ± 27.0 1.8 ± 7.8 4.3 ± 12.4
Hospitalised in the past 6 months 696 (5.4%) 144 (20.7%) 78 (11.2%) 314 (45.1%) 16023.0%)
Out-patient clinic in the past 6 months 11 780 (91.6%) 2795 (23.7%) 1686 (14.3%) 4899 (41.6%) 2400 (20.4%)
Hospitalised days 0.8 ± 4.2 0.5 ± 2.9 0.6 ± 5.1 0.9 ± 4.6 0.9 ± 4.1
Out-patient clinic times 5.8 ± 5.2 4.6 ± 4.2 4.1 ± 4.2 6.9 ± 5.5 6.2 ± 5.8
FPG, fasting plasma glucose; HBA1C, glycated haemoglobin
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Table III. Dose titration model analysis in the past 6 months Multivariate-logistic (Reference group = No titration)
Tabela III. Wieloczynnikowa analiza regresji logistycznej modelu dostosowywania dawki w ciągu ostatnich 6 miesięcy (grupa 
odniesienia = brak dostosowywania dawki)
Variables OR(CI%) P
Hospital level
Tertiary Hospital vs. Secondary Hospital Self-titration 0.904 (0.800, 1.021) 0.1041
Tertiary Hospital vs. Secondary Hospital  
Tertiary Hospital vs. Secondary Hospital
Physicians-led titration 0.901 (0.818, 0.993) 0.0359
Cooperation-led titration 0.831 (0.739, 0.933) 0.0018
Age (years)  Self-titration 0.996 (0.989, 1.002) 0.2009
 Physicians-led titration 0.997 (0.992, 1.002) 0.2867
 Cooperation-led titration 0.986 (0.980, 0.993) < 0.0001
BMI (kg/m2)  Self-titration 1.023 (1.005, 1.041) 0.0123
 Physicians-led titration 1.008 (0.994, 1.022) 0.2626
 Cooperation-led titration 1.025 (1.008, 1.042) 0.0035
Education degree  Self-titration 1.067 (1.008, 1.129) 0.0243
 Physicians-led titration 0.950 (0.908, 0.995) 0.0291
 Cooperation-led titration 0.941 (0.890, 0.994) 0.0290
Patient resource
In-patient ward Vs Out-patient clinic Self-titration 1.361 (1.203, 1.540) < 0.0001
In-patient ward Vs Out-patient clinic Physicians-led titration 2.771 (2.514, 3.055) < 0.0001
In-patient ward Vs Out-patient clinic Cooperation-led titration 3.026 (2.695, 3.397) < 0.0001
Diabetes duration (year)  Self-titration 1.022 (1.010, 1.034) 0.0004
 Physicians-led titration 1.012 (1.002, 1.021) 0.0175
 Cooperation-led titration 1.017 (1.005, 1.029) 0.0038
Macro complication
Yes vs. No Self-titration 0.989 (0.840, 1.165) 0.8975
Yes vs. No Physicians-led titration 1.081 (0.947, 1.235) 0.2496
Yes vs. No Cooperation-led titration 1.250 (1.071, 1.459) 0.0046
Micro complication
Yes vs. No Self-titration 1.272 (1.118, 1.448) 0.0003
Yes vs. No Physicians-led titration 1.014 (0.911, 1.127) 0.8043
Yes vs. No Cooperation-led titration 1.230 (1.085, 1.395) 0.0012
HbA1c at V1 (%)  Self-titration 1.079 (1.047, 1.113) < 0.0001
 Physicians-led titration 1.095 (1.068, 1.122) < 0.0001
 Cooperation-led titration 1.139 (1.107, 1.173) < 0.0001
Home blood glucose monitor 
Yes vs. No Self-titration 1.640 (1.428, 1.884) < 0.0001
Yes vs. No Physicians-led titration 1.064 (0.955, 1.184) 0.2600
Yes vs. No Cooperation-led titration 1.983 (1.735, 2.266) < 0.0001
SMBG times  Self-titration 1.011 (1.002, 1.020) 0.0137
 Physicians-led titration 1.026 (1.018, 1.033) < 0.0001
 Cooperation-led titration 1.029 (1.020, 1.037) < 0.0001
Encouraged self-titration 
Yes vs. No Self-titration 1.695 (1.505, 1.909) < 0.0001
Yes vs. No Physicians-led titration 0.927 (0.839, 1.023) 0.1321
Yes vs. No Cooperation-led titration 2.140 (1.911, 2.396) < 0.0001
Hospitalized 
Yes vs. No Self-titration 0.831 (0.624, 1.107) 0.2059
Yes vs. No Physicians-led titration 1.386 (1.124, 1.708) 0.0023
Yes vs. No Cooperation-led titration 1.420 (1.112, 1.812) 0.0049
Out-patient clinic 
Yes vs. No Self-titration 0.814 (0.688, 0.962) 0.0161
Yes vs. No Physicians-led titration 2.440 (2.064, 2.884) < 0.0001
Yes vs. No Cooperation-led titration 2.148 (1.746, 2.643) < 0.0001
BMI, body mass index; CI, confidence interval; HbA1C, glycated haemoglobin; OR, odds ratio; SMBG, self-monitoring of blood glucose
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B, C, and D, respectively. A survey conducted in China 
[11] revealed that 34% of Chinese T2DM patients are 
treated with insulin. However, only 27% of these patients 
achieved the standard HbA1C of < 7%, with a mean 
disease duration of 3.7 years. In the present study, the 
average disease duration of patients was 6.5, 7.1, 6.8, 
and 6.9 years in group A, B, C, and D, respectively. One 
of the possible reasons for not achieving the standard 
HbA1C level was that patients started receiving insulin 
treatment a little late. Although the compliance rate of 
HbA1C was low, 24.8% of these patients did not adjust 
their insulin dose, and 15.3% of patients performed self-
titration after six months of treatment in our study. The 
self-management of patients is essential for diabetes treat-
ment and is highly recommended by guidelines world-
wide. However, in real-world settings, the proportion of 
patients who did not adjust their insulin dose was high 
and the proportion of self-titration was low. Our study 
showed that fewer patients were encouraged to perform 
self-titration in the no-insulin-titration group. In clinical 
practice, physicians are required to fully understand the 
situation of patients receiving insulin for the first time and 
provide psychological counselling when necessary. This 
would help reduce the psychological burden of insulin 
treatment. In addition, physicians should encourage 
and instruct patients to adjust their insulin dose on their 
own to achieve better glycaemic control. The guidelines 
also recommend that, following the initiation of insulin 
therapy, physicians should positively encourage their 
patients to adjust their insulin dose, and should provide 
psychological counselling in order to encourage and teach 
patients to self-adjust their insulin dose.
Furthermore, the present study also revealed that 
patients who owned a glucometer were more likely to 
perform insulin dose adjustment. SMBG performance 
and higher frequency of SMBG had a positive effect 
on insulin dose adjustment in the present study. Some 
studies [13, 19, 20] have assessed the effect of SMBG con-
trol on HbA1C in type-1 and type-2 diabetes patients. 
The American Diabetes Association and Chinese guide-
lines for diabetes self-management recommend SMBG 
as an important tool in diabetes self-management. In 
the present study, 42.3%, 47.5%, 43.3%, and 49.3% of 
patients in group A, B, C, and D, respectively, owned 
a glucometer, and the frequency of SMBG in these groups 
was 5.3, 5.8, 5.0, and 5.3 times/month, respectively. After 
six months of follow-up, the percentage of patients 
who owned a glucometer in each of the four groups in-
creased to 59.3%, 71.8%, 61.8%, and 74.8%, respectively, 
and the average frequency of SMBG increased to 5.5, 
6.6, 6.5, and 7.5 times/month, respectively. Nonetheless, 
both factors were at a markedly low level. In China, 
glucometers and glucose test strips are not included in 
the medical insurance system, which may be the reason 
for the low level of SMBG in this population. This sug-
gests that it is necessary to enhance the education of 
patients and improve national medical system policies 
as a way to encourage patients to conduct SMBG. Such 
measures would also help in insulin dose adjustment 
and increase compliance to target HbA1C levels. 
To the best of our knowledge, this study is the first 
to evaluate the present situation of insulin titration in 
real-world clinical settings in China. More importantly, 
this is the first study that employed a large sample size 
comparing different insulin adjustments and investigate 
the factors that affect insulin adjustment in real-world 
settings. In this large observational study, patients with 
self-adjustment of insulin dose, physician-led insulin 
dose adjustment, and combined physician and patient-
led adjustment experienced a reduction in their HbA1C 
levels. The HbA1C achievement rate was similar across 
the three groups (groups B, C, and D), with a consider-
ably low incidence of severe hyperglycaemia events. 
Physician-led insulin dose adjustment accounted for 
40–50% of the overall dose adjustment. However, self-led 
adjustment was associated with fewer clinic visits and 
lower costs. The effectiveness and safety of long-acting 
insulin over basal insulin therapy have been confirmed 
through a large number of randomised, controlled clini-
cal studies. In the present study, the rate of hyperglycae-
mia events was similar and low in all four groups, sug-
gesting that patients initiating basal insulin therapy can 
be encouraged to adjust their insulin dose on their own.
The present study has some limitations. First, this 
was an observational study, and the patient’s treatment 
and follow-up were based on the physician’s decision 
and the patient’s willingness, which differs from the de-
sign of a randomised, controlled clinical study. Second, 
because the enrolled patients did not fully complete 
the required visits, no visits for laboratory tests were 
conducted, and patient data were only collected from 
patient information forms, there is a possibility of bias. 
In addition, some data were self-reported by patients, 
such as the frequency of hypoglycaemia and SMBG, 
which may not be accurate. Despite these limitations, 
the large sample size of the study is highly representa-
tive of the dose adjustment patterns in real-life clinical 
practice, with a preliminary exploration of factors that 
affect insulin treatment.
Conclusions
The present study is the largest in China to evalu-
ate the factors that impact type 2 patients  insulin dose 
adjustment while initiating basal insulin treatment in 
real-world clinical settings. It may help to find some 
problems and barriers in the initiation and titration of 
basal insulin. High HbA1C level, SMBG, long disease 
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duration, microvascular complications, and the encour-
agement of physicians prompt patients to perform dose 
adjustments.
Implications/relevance for diabetes educators
Our study shows that encouragement from physicians 
is positively related with insulin self-adjustment. The 
findings suggest that when a patient starts to use insulin 
treatment, encouragement from physician is a key fac-
tor to seek insulin adjustment. Therefore, in real-world 
clinical settings, diabetes educators should encourage 
patients to adjust their insulin dose on their own. This 
is helpful for patients to achieve better glucose control. 
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